Pseudo-PDT in Central Serous Chorioretinopathy

Università degli Studi di Brescia22 enrolled

Overview

Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC. Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Central Serous Chorioretinopathy

Interventions

689 nm Laser Treatment of the MaculaPROCEDURE

Half Dose Photodynamic TherapyPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age ≥18 years; * patients with best-corrected visual acuity (BCVA) of 20/200 or better; * presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment involving the fovea on optical coherence tomography (OCT); * presence of active angiographic leakage in fluorescein angiography caused by CSC and no other diseases, and abnormal dilated choroidal vasculature and other features in indocyanine green angiography (ICGA) consistent with the diagnosis of CSC. Exclusion Criteria: * any previous treatment for CSC; * evidence of choroidal neovascularization or other maculopathy on fundus examination.

Outcomes

Primary Outcomes

Best-corrected Visual Acuity (LogMAR)

Measured with ETDRS chart

Time frame: 6 months

Central Retinal Thickness (micron)

Measured with OCT

Time frame: 6 months

Subfoveal Choroidal Thickness (micron)

Measured with OCT

Time frame: 6 months

Secondary Outcomes

Ellipsoid Zone Recovery (integrity of IS/OS line)

As visible with OCT scans

Time frame: 6 months

Central Contacts

Andrea Russo, MD, PhD

CONTACT

+390303995308 dott.andrea.russo@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.